SARS1-Related Neurodevelopmental Disorder — Comprehensive Research Report

1. Disease Information

Overview. SARS1-related neurodevelopmental disorder — formally designated Neurodevelopmental Disorder with Microcephaly, Ataxia, and Seizures (NEDMAS) — is an ultra-rare, autosomal recessive Mendelian disorder caused by biallelic (and in one reported case, a dominant-negative de novo) pathogenic variants in SARS1, the gene encoding cytoplasmic seryl-tRNA synthetase 1. The core phenotype comprises global developmental delay/intellectual disability, postnatal microcephaly, early-onset seizures, ataxia, and muscle weakness, with an expanding phenotypic spectrum that now includes sensorineural deafness, cardiomyopathy, fever-triggered metabolic decompensation (in loss-of-function cases), and — in a distinct de novo dominant-negative case — complex spastic paraplegia without microcephaly (Musante et al. 2017, PMID:28236339; Ravel et al. 2021, PMID:34570399; Bögershausen et al. 2022, PMID unlisted; Karaca-Mandic/Turkish cohort 2022, PMID:36004946; PMID:36041817).

Key identifiers: - Gene: SARS1 (formerly SARS), HGNC:10537, located at chromosome 1p13.3 - OMIM gene: 607529 — Seryl-tRNA Synthetase 1; SARS1 (OMIM:607529) - OMIM phenotype: #617709 — Neurodevelopmental Disorder with Microcephaly, Ataxia, and Seizures (NEDMAS) (OMIM:617709) - Suggested MONDO ID: should correspond to the MONDO term cross-referenced to OMIM:617709 (mint via the standard OMIM→MONDO xref if not already in the local ontology cache; a specific MONDO CURIE could not be independently confirmed from public search results and should be verified with OAK against sqlite:obo:mondo before curation) - Inheritance: Autosomal recessive (most reported families); one de novo dominant-negative case reported - Category: Mendelian, aminoacyl-tRNA synthetase (ARS) disorder

Synonyms/alternative names: NEDMAS; SARS1 deficiency; seryl-tRNA synthetase 1 deficiency; SARS-related intellectual disability (older literature, pre-2017/pre-gene-renaming used "SARS" rather than "SARS1" since the gene was renamed from SARS to SARS1 to distinguish from unrelated "SARS" coronavirus nomenclature).

Important disambiguation: SARS1 encodes the cytoplasmic seryl-tRNA synthetase and must not be confused with SARS2, which encodes the mitochondrial seryl-tRNA synthetase and causes a clinically distinct disorder (HUPRA syndrome — hyperuricemia, pulmonary hypertension, renal failure, alkalosis). Web search results returning SARS2/mitochondrial content were explicitly filtered out of this report; all findings below pertain to the cytoplasmic SARS1 gene only.

Evidence source note: Information below is aggregated from published case series/case reports (peer-reviewed literature, disease-level aggregation) rather than large-cohort EHR data, consistent with an ultra-rare Mendelian disorder with fewer than ~15 reported individuals across all published families as of the most recent (2022) case series.

2. Etiology

Disease causal factors: Purely genetic/monogenic. Biallelic (homozygous or compound heterozygous) missense variants in SARS1 are the predominant mechanism, causing partial loss of seryl-tRNA synthetase aminoacylation function. A single reported case involves a de novo, dominant-negative, in-frame splice-altering deletion producing a distinct, non-microcephalic spastic paraplegia phenotype via a toxic gain-of-function/dominant-negative mechanism rather than simple biallelic loss-of-function (PMID:36041817).

Genetic risk factors: - Reported pathogenic variants (all missense unless noted): - c.514G>A, p.(Asp172Asn) — homozygous, consanguineous Iranian family, 4 affected siblings (Musante et al. 2017, PMID:28236339) - p.(Arg302Cys) and p.(Arg390Cys) — compound heterozygous, second Iranian family (Musante et al. 2017) - c.638G>T, p.(Arg213Leu) — homozygous, consanguineous Turkish family; associated with the deafness/cardiomyopathy/fever-decompensation phenotype (Ravel et al. 2021, PMID:34570399) - c.1196C>T, p.(Thr399Met) — novel missense variant identified in multiple unrelated Turkish NEDMAS families (biallelic) (2022 clinical spectrum expansion, PMID:36004946) - chr1:109778053_109778055delGGT (genomic deletion spanning the exon 7/intron 7 boundary) — de novo, heterozygous, splice-site-disrupting deletion causing in-frame insertion of 16 intronic bp / 5 aberrant amino acids near the enzyme active site; dominant-negative mechanism (PMID:36041817) - Additional biallelic missense variants reported in a 2022 multi-gene series alongside WARS1 cases, in individuals presenting with an overlapping microcephaly/developmental-delay/brain-anomaly phenotype (Bögershausen et al. 2022) - Consanguinity is a recurring feature across nearly all reported pedigrees (Iranian and Turkish families), consistent with autosomal recessive transmission and suggesting the disorder is substantially under-ascertained outside consanguineous populations. - No modifier genes or susceptibility loci have been reported to date; no GWAS/PheGenI signal exists given the extreme rarity and Mendelian nature of the condition.

Environmental risk factors / gene-environment interaction: The most clinically significant gene-environment interaction reported is febrile illness as a precipitant of acute decompensation. In the Ravel et al. (2021) family, affected children experienced severe metabolic/neurological decompensation during febrile episodes, in one case fatal, indicating that fever/infectious stress unmasks or exacerbates an underlying translational insufficiency — a pattern seen in several other aminoacyl-tRNA synthetase disorders where impaired global protein synthesis becomes rate-limiting under increased physiological demand. In the spastic-paraplegia case (PMID:36041817), seizures were "frequently precipitated by fever" as well, reinforcing fever as a cross-cutting trigger for this gene.

Protective factors: None reported in the literature; given the rarity of the disorder, no population-level protective variant or environmental protective factor data exists in gnomAD/GWAS resources specific to SARS1-NEDMAS.

3. Phenotypes

Phenotype burden is drawn from the aggregate of published cases (Musante 2017, n=5 across 2 families; Ravel 2021, n=2 siblings; the 2022 Turkish cohort, n=4 across 3 families; Bögershausen 2022, additional individuals; and the single spastic-paraplegia case). Because the total published cohort is small (~12-15 individuals), frequencies below are qualitative/descriptive rather than statistically robust percentages.

Onset: Infantile to early childhood in virtually all reported cases (developmental delay and/or seizures typically noted in infancy/toddlerhood).

Severity/progression: Variable — ranges from moderate intellectual disability with stable ataxia (original Iranian family) to severe, fatal fever-triggered decompensation (Ravel et al. Turkish family) to a progressive-then-stabilizing spastic paraparesis (de novo case). This variability appears to correlate with variant type/mechanism (partial loss-of-function missense vs. dominant-negative splice variant vs. more severe loss-of-function variant with organ involvement).

Quality of life impact: Not formally studied with standardized instruments (EQ-5D/SF-36/PROMIS) in the literature; qualitatively, the combination of intellectual disability, seizures, ataxia, and (in some cases) cardiomyopathy/deafness confers substantial impact on daily functioning, communication, and mobility, with life-threatening risk during febrile illness in the loss-of-function subgroup.

4. Genetic/Molecular Information

Causal gene: SARS1 (HGNC:10537; NCBI Gene ID 6301; OMIM *607529), chromosome 1p13.3, encoding cytoplasmic seryl-tRNA synthetase (protein SerRS/SYSC).

Gene function: SARS1 catalyzes the ATP-dependent aminoacylation of tRNA^Ser with L-serine — the first step of incorporating serine into nascent polypeptides during cytoplasmic translation. It also catalyzes the first step of selenocysteine (Sec) biosynthesis, since Sec-tRNA is initially charged with serine by SerRS before conversion to selenocysteine, giving SARS1 a secondary non-canonical role connecting it to selenoprotein synthesis. Notably, zebrafish studies (Fukui et al. 2009; Herzog et al. 2009) showed that Sars also has an aminoacylation-independent role in vascular development, indicating this synthetase family member has moonlighting functions beyond canonical translation.

Protein structure: SARS1 is a Class II aminoacyl-tRNA synthetase (aaRS) that functions as a homodimer in the cytoplasm (distinguishing it structurally/mechanistically from Class I aaRSs). Structural modeling of the de novo splice variant showed the aberrant 5-amino-acid in-frame insertion disrupts a critical β-strand near the catalytic core and displaces residues essential for ATP and serine substrate recognition, directly implicating the active site in pathogenesis for that variant (PMID:36041817).

Pathogenic variant classes reported: - Missense (majority of biallelic cases): p.Asp172Asn, p.Arg302Cys, p.Arg390Cys, p.Arg213Leu, p.Thr399Met, plus additional biallelic missense variants in the Bögershausen 2022 series - Splice-region genomic deletion (single de novo case): chr1:109778053_109778055delGGT, producing an in-frame 5-amino-acid insertion rather than a frameshift/null allele

Variant classification (ACMG/AMP): Not explicitly stated per-variant in the sources retrieved; given segregation in consanguineous families with clinical concordance and (for the de novo splice variant) direct functional/structural evidence, these variants would likely be classified pathogenic or likely pathogenic under ACMG/AMP criteria (PS2/PS3/PM1/PM2/PP1/PP3-type evidence), but formal ClinVar submission status should be independently verified.

Allele frequency: Not reported as present at appreciable frequency in population databases (gnomAD, 1000 Genomes) — consistent with an ultra-rare recessive disorder; specific gnomAD allele counts were not retrievable from the search results and should be checked directly in gnomAD/ClinVar during curation.

Functional consequences: - Biallelic missense variants (loss-of-function, partial): reduce SARS1 aminoacylation activity, impairing global cytoplasmic protein synthesis capacity — most evident under physiological stress (fever). - De novo splice deletion: dominant-negative mechanism — patient fibroblasts showed ~30% reduced aminoacylation activity, and yeast complementation studies demonstrated that co-expression of wild-type and mutant SARS1 produced significant growth defects, confirming a poisoning/dominant-negative effect of the mutant protein on the wild-type homodimer, rather than simple haploinsufficiency (PMID:36041817).

Somatic vs. germline: All reported variants are germline (constitutional); no somatic/cancer association has been reported for SARS1.

Modifier genes: None established.

Epigenetic information: No DNA methylation, histone modification, or chromatin-level disease mechanism has been reported for SARS1-NEDMAS in the retrieved literature.

Chromosomal abnormalities: None reported; disease mechanism is point-variant/small-indel based, not large structural rearrangement.

5. Environmental Information

• Environmental factors: No toxin, radiation, or occupational exposure has been implicated as a primary or contributing cause; this is a monogenic disorder.
• Lifestyle factors: Not applicable as a causal factor; however, febrile illness management (see below) is a critical environmental/clinical modifier of disease course.
• Infectious agents: No specific pathogen is causally implicated in disease onset. However, febrile infectious illness (of any etiology) acts as a non-specific environmental trigger for acute decompensation and seizure exacerbation in affected individuals — this is a gene-level vulnerability to physiological/metabolic stress rather than an infection-specific mechanism, analogous to fever-sensitivity patterns seen in other mitochondrial/translational disorders (e.g., RARS2-related pontocerebellar hypoplasia) and in certain channelopathies.

6. Mechanism / Pathophysiology

Causal chain (loss-of-function/biallelic missense pathway): 1. Biallelic missense variant in SARS1 → partially impaired seryl-tRNA synthetase aminoacylation activity (charging of tRNA^Ser with serine) 2. Reduced/inefficient charging of tRNA^Ser → globally reduced or qualitatively impaired cytoplasmic protein synthesis, with likely selective vulnerability of high-translation-demand tissues (developing CNS, cardiac muscle, cochlea) 3. Chronic translational insufficiency during development → microcephaly, ataxia, intellectual disability, cardiomyopathy, sensorineural deafness (organ-specific manifestations depending on variant severity/tissue vulnerability) 4. Acute physiological stress (fever) → further reduction in translational capacity relative to increased metabolic demand → acute neurological/metabolic decompensation, in the most severe reported case leading to death

Causal chain (de novo dominant-negative pathway — distinct disease mechanism): 1. De novo in-frame splice-disrupting deletion → mutant SARS1 protein with an aberrant 5-residue insertion near the catalytic/ATP-serine-binding active site 2. Mutant monomer co-assembles with wild-type monomer in the obligate homodimer → dominant-negative poisoning of overall enzyme activity (~30% reduction in aminoacylation measured in patient fibroblasts; confirmed via yeast complementation growth-defect assay) 3. Reduced translational fidelity/capacity, plus an SARS1-specific non-canonical consequence: patient fibroblasts show a cellular senescence phenotype — reduced proliferation, abnormal morphology, increased senescence-associated beta-galactosidase staining, elevated phosphorylated histone H2AX (a DNA-damage-response marker), and markedly increased expression of senescence-associated secretory phenotype (SASP) genes (IL-6, p21, p16, p53) 4. This senescence-driving mechanism is described as unique among known aminoacyl-tRNA synthetases and represents a newly characterized pathway linking translational-machinery dysfunction to cellular aging/senescence programs, plausibly contributing to the progressive-then-stabilizing spastic paraparesis and CNS findings in this specific patient — distinct from the classic microcephaly-predominant biallelic phenotype (PMID:36041817)

Cellular processes involved: - Cytoplasmic mRNA translation (core aminoacylation step) - Cellular senescence / SASP activation (de novo dominant-negative case) - DNA damage response (elevated γH2AX) - Possible selenoprotein synthesis impairment (via the Sec-tRNA charging role of SerRS), though this has not been directly demonstrated as pathogenic in NEDMAS

Protein dysfunction: Loss-of-function (reduced catalytic aminoacylation activity) is the primary mechanism for biallelic missense variants; the single de novo case is best characterized as dominant-negative (not simple gain-of-function toxicity, but interference with wild-type enzyme function in the obligate dimer).

Cell types and biological processes (suggested ontology terms): - GO:0006434 seryl-tRNA aminoacylation (molecular process directly disrupted) - GO:0006412 translation (downstream biological process impaired) - GO:0090398 cellular senescence (mechanism specific to the de novo dominant-negative case) - GO:0006974 DNA damage response (elevated γH2AX in senescent fibroblasts) - CL:0000057 fibroblast (primary patient-derived cell type used for functional studies) - CL:0000540 neuron (presumed primary affected cell type given CNS-predominant phenotype, though not directly assayed in these studies) - CL:0000187 myocyte / cardiac muscle cell (relevant to the cardiomyopathy phenotype in the Ravel et al. family)

Tissue damage mechanisms: Not characterized at the histopathological level in the retrieved literature (no biopsy/autopsy data reported); mechanism is inferred from functional/biochemical assays in patient fibroblasts and heterologous (yeast) complementation systems rather than direct tissue pathology.

Molecular profiling: No transcriptomic, proteomic, or metabolomic dataset specific to SARS1-NEDMAS patient tissue was identified in the retrieved sources beyond the targeted qPCR-level SASP gene expression analysis (IL-6, p21, p16, p53) described above.

7. Anatomical Structures Affected

• Organ level (primary): Central nervous system (brain — cerebrum and cerebellum), consistent with the microcephaly/ataxia/seizure triad
• Organ level (secondary, variant-dependent): Inner ear/cochlea (sensorineural deafness — Ravel et al. family); heart (cardiomyopathy — Ravel et al. family); skeletal muscle (weakness, spasticity)
• Body systems involved: Nervous system (primary), cardiovascular system (secondary, in loss-of-function severe phenotype), auditory system (secondary), musculoskeletal system (motor/spasticity findings)
• Tissue/cell level: Neurons and glial elements of cerebral cortex and cerebellum (inferred from atrophy on neuroimaging); cardiomyocytes; cochlear hair cells/auditory neurons (inferred, not directly biopsied); dermal fibroblasts (directly studied ex vivo in the functional characterization of the de novo variant)
• Subcellular level: Cytoplasm (site of SARS1 enzymatic activity — GO Cellular Component GO:0005737 cytoplasm / more specifically GO:0017101 aminoacyl-tRNA synthetase multienzyme complex); nucleus (site of γH2AX DNA damage marker accumulation in senescent cells, GO:0005634)
• Localization (UBERON): UBERON:0000955 brain; UBERON:0002037 cerebellum; UBERON:0000956 cerebral cortex; UBERON:0001690 ear / UBERON:0001846 cochlea (deafness phenotype); UBERON:0000948 heart (cardiomyopathy phenotype)
• Lateralization: Bilateral/symmetric involvement reported (bilateral cerebral and cerebellar atrophy in the Turkish cohort neuroimaging)

8. Temporal Development

• Onset: Infantile to early childhood for developmental delay and seizures; postnatal microcephaly (implying normal or near-normal head circumference at birth with subsequent deceleration, though this was not explicitly confirmed as congenital vs. postnatal across all cases in the retrieved sources — recommend verifying per-case in the primary papers before curating an onset_category)
• Onset pattern: Insidious/progressive for developmental delay; acute/episodic for fever-triggered decompensation and seizures
• Progression: Variable by genotype —
• Biallelic missense (classic NEDMAS): chronic, relatively stable developmental impairment punctuated by acute febrile decompensation risk
• De novo dominant-negative: spastic paraparesis "worsened during childhood but later stabilized" — a distinctive non-monotonic (progressive-then-plateauing) course
• Disease course pattern: Chronic with episodic acute crises (fever-triggered) in the severe loss-of-function subgroup; chronic-stable to chronic-progressive-then-stable in the dominant-negative case
• Disease duration: Lifelong/chronic; at least one reported case was fatal in childhood due to fever-triggered decompensation (Ravel et al. 2021)
• Critical periods: Febrile illness represents an identifiable window of acute vulnerability across multiple reported cases, suggesting a clinically actionable "critical period" for aggressive fever management/monitoring in affected individuals, though this has not been formalized into a published clinical protocol.

9. Inheritance and Population

• Epidemiology: No formal prevalence or incidence estimate exists; this is an ultra-rare disorder with fewer than ~15 individuals reported in the peer-reviewed literature across all publications identified (2017–2022+). No entry in large disease-registry/GBD-type databases was identified.
• Inheritance pattern: Autosomal recessive for the classic NEDMAS phenotype (all biallelic cases, occurring predominantly in consanguineous Iranian and Turkish families); autosomal dominant, de novo for the single reported spastic-paraplegia case with a dominant-negative mechanism.
• Penetrance: Presumed complete for the recessive form given consistent phenotype in all biallelic carriers reported to date, though the small sample size limits confidence.
• Expressivity: Clearly variable — phenotype ranges from moderate ID/ataxia (original Iranian family) to fatal fever-triggered decompensation with deafness/cardiomyopathy (Turkish family) to spastic paraplegia without microcephaly (de novo case) — indicating genotype-phenotype correlation by variant/mechanism rather than uniform expressivity.
• Genetic anticipation: Not reported/not applicable (no repeat-expansion mechanism).
• Germline mosaicism: Not specifically reported.
• Founder effects: Not established, though the recurrence of specific consanguineous-family variants (e.g., p.Thr399Met recurring across multiple unrelated Turkish families) raises the possibility of a Turkish population founder variant — this warrants further population-genetic study but was not explicitly confirmed as a founder effect in the retrieved sources.
• Consanguinity role: Prominent — most reported pedigrees (Iranian families in Musante et al. 2017; Turkish families in Ravel et al. 2021 and the 2022 cohort) are consanguineous, consistent with autosomal recessive transmission of rare alleles.
• Carrier frequency: Not established in population databases.
• Affected populations: Reported cases cluster in Iranian and Turkish consanguineous families; no data on other ethnic/geographic groups, likely reflecting ascertainment bias toward populations with higher consanguinity rates and active clinical genetics/exome-sequencing research programs rather than true population restriction.
• Sex ratio: Not reported as skewed; autosomal recessive/dominant inheritance would not a priori predict a sex bias, and no such bias was noted in the retrieved case descriptions.
• Age distribution: Reported cases span infancy through early adolescence (the de novo case patient is described as an "early adolescent male" at time of report).

10. Diagnostics

• Genetic testing (primary diagnostic modality): Diagnosis in all reported cases was established via whole-exome sequencing (WES), either trio-based (de novo case, and Musante et al. 2017 original families) or proband/family-based (Turkish cohort, 2022). This reflects current clinical practice for undiagnosed neurodevelopmental disorders generally — WES/WGS with subsequent Sanger confirmation and segregation analysis in the family.
• Single-gene testing: Feasible via Sanger sequencing once a familial variant is known (e.g., for prenatal or carrier testing in a family with a previously identified proband).
• Gene panels: SARS1 would reasonably be included in comprehensive intellectual-disability/microcephaly/epilepsy gene panels, though no specific commercial panel was identified in the retrieved sources; the NIH Genetic Testing Registry (GTR) lists SARS1 as a testable gene (GTR gene 6301).
• Chromosomal microarray/karyotype/FISH: Not applicable as primary diagnostic tools (disease is caused by point variants/small indels, not large structural rearrangements), though these are typically part of the standard diagnostic workup to exclude other causes of ID/microcephaly before or alongside sequencing.
• Imaging: Brain MRI is diagnostically informative — bilateral cerebral and cerebellar atrophy was reported in the Turkish cohort; the de novo case showed subtle, non-progressive punctiform frontal subcortical white-matter hyperintensities, a distinguishing (milder) imaging pattern.
• Electrophysiology: Visual evoked potentials showed increased latency in the de novo case, suggesting a role for VEP/electrophysiological testing in characterizing CNS involvement; EEG would be standard given the seizure phenotype (not explicitly detailed in retrieved abstracts).
• Functional/biochemical testing: Not part of routine clinical diagnosis; aminoacylation activity assays and yeast complementation studies were research-level functional validation tools used to confirm variant pathogenicity in the de novo case, not standard-of-care diagnostics.
• Differential diagnosis: Other autosomal recessive/dominant aminoacyl-tRNA synthetase disorders (e.g., WARS1-related recessive microcephaly — a close mimic per Bögershausen et al. 2022 — as well as RARS2-related pontocerebellar hypoplasia type 6, KARS1-, VARS1-, NARS1-related neurodevelopmental disorders), other causes of primary microcephaly with intellectual disability and ataxia, and mitochondrial encephalopathies (given phenotypic overlap with fever-triggered decompensation) should be considered and excluded.
• Screening: No newborn screening or population carrier-screening program exists for this ultra-rare condition.

11. Outcome/Prognosis

• Survival/mortality: At least one reported case (Ravel et al. 2021 family) was fatal due to fever-triggered metabolic/neurological decompensation, establishing that the loss-of-function/severe end of the phenotypic spectrum carries meaningful mortality risk, particularly around febrile illness. No formal survival statistics (5-year/10-year) exist given the tiny reported cohort.
• Morbidity/function: Chronic, lifelong intellectual disability, ataxia, and (in some cases) spasticity impose significant functional impairment; no standardized disability or QOL outcome measures have been published for this condition.
• Disease course: As above — chronic-stable to chronic-progressive-then-stabilizing (de novo case), or chronic-with-acute-crisis-risk (loss-of-function biallelic cases).
• Complications: Fever-triggered acute decompensation (potentially fatal); cardiomyopathy (loss-of-function severe phenotype); progressive spasticity (de novo case, though noted to stabilize later in that individual).
• Prognostic factors: Variant type/mechanism appears to be the dominant prognostic factor identified to date — biallelic partial-loss-of-function missense variants with organ involvement (deafness, cardiomyopathy) carry the most severe/potentially fatal course; the de novo dominant-negative variant produced a phenotype without microcephaly and with a plateauing motor course. No molecular biomarker has been established as a prognostic tool.

12. Treatment

No SARS1/NEDMAS-specific approved therapy exists. Management reported in the literature is supportive/symptomatic:

• Supportive care: Management of seizures (standard antiepileptic approaches, implied but not itemized by specific agent in the retrieved abstracts), and — critically — aggressive management of febrile illness to prevent metabolic/neurological decompensation, given the clear fever-precipitant pattern documented across multiple families. This should be considered a de facto tertiary-prevention/critical-management principle for this disorder even though no formal clinical guideline was identified.
• Rehabilitative therapies: Physical therapy, occupational therapy, and speech therapy would be standard supportive interventions for the motor (ataxia, spasticity) and speech-delay phenotypes, consistent with general neurodevelopmental disorder management, though not specifically itemized in the retrieved case reports.
• Suggested NCIT terms: NCIT:C15302 (Physical Therapy), NCIT:C159273 (Speech Therapy), NCIT:C121351 (Occupational Therapy)
• Cardiac management: Cardiology follow-up/management would be indicated for the subset of patients with cardiomyopathy (Ravel et al. family) — NCIT:C49236 (Therapeutic Procedure)/standard heart-failure management, not itemized specifically.
• Audiology: Hearing evaluation and intervention (hearing aids/cochlear implant as indicated) for the sensorineural deafness subgroup.
• Genetic counseling: Indicated given autosomal recessive inheritance in consanguineous families, for recurrence-risk counseling and potential prenatal/preimplantation testing in subsequent pregnancies. NCIT:C15240 (Genetic Counseling).
• Experimental/investigational therapy: No SARS1-specific gene therapy, RNA-based therapy, or targeted molecular therapy has reached clinical trials; no ClinicalTrials.gov entries specific to SARS1-NEDMAS were identified in the retrieved search results. Broader aaRS-disorder research literature discusses conceptual therapeutic strategies applicable to this gene family in principle — amino acid supplementation, tRNA overexpression, modulation of integrated stress response, and genome editing — but these remain investigational/preclinical concepts rather than SARS1-specific interventions (PMC11611227).

13. Prevention

• Primary prevention: Not applicable in the traditional sense (monogenic disorder); the only actionable primary-prevention-adjacent measure is genetic counseling and carrier/prenatal testing in families with a known pathogenic variant, particularly relevant given the strong consanguinity pattern in reported pedigrees.
• Secondary prevention: Early diagnosis via WES in infants/children presenting with unexplained developmental delay, microcephaly, ataxia, and seizures enables anticipatory guidance (e.g., heightened vigilance and aggressive antipyretic/supportive management during febrile illness) that may mitigate the risk of severe/fatal decompensation identified in the Ravel et al. family.
• Tertiary prevention: Aggressive, proactive management of febrile illness (the clearest identified modifiable risk factor for acute decompensation) constitutes the most concrete tertiary-prevention strategy supported by the literature, though it has not been codified into a formal published clinical protocol or guideline.
• Screening/genetic counseling: Carrier screening is not population-based (given rarity) but should be offered to at-risk consanguineous families with a known proband; preimplantation genetic diagnosis (PGD) would be a reasonable option for families with an identified pathogenic variant, consistent with standard practice for autosomal recessive Mendelian disorders, though not explicitly documented as having been used in these specific families.

14. Other Species / Natural Disease

• Taxonomy/model relevance: Zebrafish (Danio rerio, NCBITaxon:7955) is the primary non-human model system referenced in the literature for sars/SARS1 biology. Fukui et al. (2009) and Herzog et al. (2009) identified zebrafish sars mutants with abnormal vascular development, and notably found this vascular role to be independent of the canonical aminoacylation function — an important non-canonical (moonlighting) function of this synthetase that is distinct from, but potentially mechanistically relevant to, its neurodevelopmental disease role in humans.
• Orthologous gene: Mouse ortholog Sars1 (NCBI Gene ID 20226, Mus musculus); no Sars1 knockout mouse model with a reported neurodevelopmental phenotype was identified in the retrieved search results — this appears to be a gap in the current model-organism literature for this specific gene (in contrast to related aaRS genes like Kars1, Vars1, and Wars1, for which zebrafish knockouts recapitulating brain/eye phenotypes have been more thoroughly characterized).
• Natural disease in companion/veterinary species: No OMIA entry or veterinary case series for naturally occurring SARS1-related disease in animals was identified.
• Comparative biology: The broader aaRS gene family shows a consistent pattern across paralogs (KARS1, VARS1, WARS1, NARS1, SARS1) of zebrafish knockouts preferentially affecting brain and eye development, mechanistically consistent with the microcephaly/CNS phenotype seen in human patients and supporting cross-paralog conservation of a dosage-sensitive requirement for aaRS activity during neurodevelopment.
• Zoonotic potential/transmission: Not applicable (non-infectious, monogenic disorder).

15. Model Organisms

• Zebrafish (Danio rerio): The most relevant existing model, though the published sars zebrafish mutants (Fukui 2009, Herzog 2009) were characterized for a vascular development phenotype, not the human neurodevelopmental (microcephaly/ataxia/seizure) phenotype — representing a translational gap. A zebrafish knock-in model of a specific human NEDMAS-causing missense variant (analogous to the KARS1 zebrafish knockout work cited for other aaRS disorders) does not appear to have been published yet for SARS1, and would be a natural follow-on model to more directly recapitulate and mechanistically dissect the human CNS phenotype.
• Yeast complementation system: Used as a functional/heterologous validation model (not a disease model per se) to demonstrate the dominant-negative growth-defect effect of the de novo splice variant when co-expressed with wild-type SARS1 — this represents an important functional-genomics tool for variant classification in this gene going forward (PMID:36041817).
• Patient-derived fibroblasts: The primary "model system" used across the functional characterization literature — patient dermal fibroblasts were used to measure aminoacylation activity (~30% reduction in the de novo case) and to characterize the cellular senescence phenotype (β-galactosidase staining, γH2AX, SASP gene expression). No iPSC-derived neuronal model specific to SARS1-NEDMAS was identified in the retrieved sources — this represents a clear opportunity for future model development given the CNS-predominant human phenotype.
• Model limitations: Current models (zebrafish vascular mutants, yeast complementation, patient fibroblasts) each capture only a partial aspect of the human disease — none directly recapitulates the CNS-specific microcephaly/ataxia/seizure phenotype in vivo, representing a significant translational gap for mechanistic and preclinical therapeutic studies in this gene.

Summary of Key Ontology Term Suggestions for Curation

Key Citations

1. Musante L, et al. "Mutations of the aminoacyl-tRNA-synthetases SARS and WARS2 are implicated in the etiology of autosomal recessive intellectual disability." Hum Mutat. 2017. PMID:28236339
2. Ravel JM, et al. "A bi-allelic loss-of-function SARS1 variant in children with neurodevelopmental delay, deafness, cardiomyopathy, and decompensation during fever." Hum Mutat. 2021 Dec;42(12):1576-1583. PMID:34570399
3. [Authors unlisted in retrieved abstract]. "Loss of seryl-tRNA synthetase (SARS1) causes complex spastic paraplegia and cellular senescence." 2022. PMID:36041817
4. Bögershausen N, Krawczyk HE, Jamra RA, et al. "WARS1 and SARS1: Two tRNA synthetases implicated in autosomal recessive microcephaly." Hum Mutat. 2022 Oct;43(10):1454-1471. Wiley DOI
5. [Turkish cohort authors unlisted in retrieved abstract]. "Neurodevelopmental disorder with microcephaly, ataxia, and seizures syndrome: expansion of the clinical spectrum." Clin Dysmorphol. 2022 Oct;31(4):167-173. PMID:36004946
6. OMIM #617709 — Neurodevelopmental Disorder with Microcephaly, Ataxia, and Seizures (NEDMAS). omim.org/entry/617709
7. OMIM *607529 — Seryl-tRNA Synthetase 1; SARS1. omim.org/entry/607529
8. Review: "Aminoacyl-tRNA synthetase defects in neurological diseases." PMC11611227

Note on gaps requiring direct primary-source verification before KB curation: Several full-text primary sources (Ravel et al. 2021, Bögershausen et al. 2022) were paywalled and only accessible via abstract/secondary summary; exact quoted snippets for evidence items should be re-verified against the cached PubMed abstracts via just fetch-reference before use, per this repository's evidence-integrity SOP. The MONDO ID and specific author lists for two papers (PMID:36041817 and PMID:36004946 full author bylines) should also be confirmed directly against PubMed/MONDO before finalizing the KB entry.